

Ref: FOI/GS/ID 8018

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

02 March 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to non-small cell lung cancer (NSCLC).

You asked:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- a. Afatinib*
- b. Alectinib*
- c. Amivantamab*
- d. Atezolizumab monotherapy*
- e. Atezolizumab with chemotherapy*
- f. Brigatinib*
- g. Ceritinib*
- h. Crizotinib*
- i. Dacomitinib*
- j. Dabrafenib with Trametinib*
- k. Durvalumab*
- l. Erlotinib*
- m. Gefitinib*
- n. Lorlatinib*
- o. Mobocertinib*
- p. Nintedanib with Docetaxel*
- q. Nivolumab*
- r. Osimertinib*
- s. Pembrolizumab monotherapy*
- t. Pembrolizumab with chemotherapy*
- u. Pemetrexed with Carboplatin/Cisplatin*
- v. Pralsetinib*
- w. Selpercatinib*

- x. *Sotorasib*
- y. *Tepotinib*
- z. *Vinorelbine with Carboplatin/Cisplatin*
- aa. *Any other active systemic anti-cancer therapy (SACT)*
- bb. *Palliative care only*

Q2. *In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:*

- a. *Atezolizumab monotherapy*
- b. *Atezolizumab with chemotherapy*
- c. *Durvalumab*
- d. *Nivolumab*
- e. *Osimertinib*
- f. *Pembrolizumab (Keytruda) Mono*
- g. *Pembrolizumab (Keytruda) with Chemotherapy*
- h. *Tepotinib*
- i. *Other active systemic anti-cancer therapy (SACT)*
- j. *Palliative care only*

Trust response:

Q1.

- a. 3
- b. 6
- c. 0
- d. 2
- e. 0
- f. 0
- g. 0
- h. 2
- i. 0
- j. 1
- k. 2
- l. 0
- m. 0
- n. 1
- o. 0
- p. 2
- q. 0
- r. 22
- s. 22
- t. 19
- u. 19
- v. 0
- w. 1
- x. 1
- y. 0
- z. 9
- aa. 6
- bb. 0

Q2.

a. 1

b. 0

c. 1

d. 0

e. 1

f. 3

g. 1

h. 0

i. 3

j. 0